Abstract 1441P
Background
The accurate detection of lymph node metastasis (LNM) in early gastric cancer (EGC) remains a challenge, conventional radical gastrectomy may not be warranted for EGC patients with a low LNM risk and a favorable prognosis. This study aims to construct a risk prediction model of lymph node metastasis based on clinicopathologic features, tumor budding, convolutional neural network, and machine learning in early gastric cancer.
Methods
Clinicopathological features and tumor budding (TB) were assessed using the image recognition software Qupath. There was a total of 1523471 patches, 260998 patches, and 166594 patches from three patient cohorts that were retrospectively analyzed. Convolutional neural networks (CNNs) were used for deep transfer learning to classify patches and extract features. LASSO regression and multiple machine learning algorithms were employed to combine CNN features with clinicopathological features. The risk prediction model was also verified in two independent validation cohorts.
Results
Among 200 patients, LNM incidence was 27.14% in the training cohort, 15.15% in the internal validation cohort, and 14.82% in the external validation cohort. Multivariate analysis identified pathological T stage and ITBCC-TB grade as independent LNM risk factors (p < 0.05). The Resnet152 CNN model demonstrated excellent performance with AUC values of 0.995, 0.988, and 0.965 in the training, internal validation, and external validation cohorts, respectively. The CNN-ML model using Gradient Boosting exhibited superior predictive capacity, with AUC values of 0.901 (95% CI 0.844-0.957), 0.871 (95% CI 0.726-0.999), and 0.804 (95% CI 0.555-0.999) in the training and two independent validation cohorts.
Conclusions
Pathological T stage and ITBCC-TB grade were identified as independent risk factors for LNM in EGC. The integration of clinicopathological features, image recognition, and deep transfer learning using CNNs resulted in a highly accurate predictive model for LNM in EGC. This model will provide valuable insights into the development of a more comprehensive and individualized approach to managing EGC, thereby improving the quality of care for affected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract